Weaver Consulting Group Increases Stock Holdings in Veru Inc. (NASDAQ:VERU)

Weaver Consulting Group raised its holdings in Veru Inc. (NASDAQ:VERU) by 41.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 69,705 shares of the company’s stock after acquiring an additional 20,280 shares during the quarter. Weaver Consulting Group’s holdings in Veru were worth $45,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in VERU. Perceptive Advisors LLC increased its holdings in shares of Veru by 26.5% during the second quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company’s stock valued at $5,942,000 after acquiring an additional 1,478,578 shares in the last quarter. PVG Asset Management Corp purchased a new stake in Veru during the 2nd quarter worth approximately $474,000. Bank of New York Mellon Corp increased its stake in Veru by 1,718.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company’s stock valued at $373,000 after purchasing an additional 419,374 shares in the last quarter. Choreo LLC raised its holdings in shares of Veru by 261.3% in the second quarter. Choreo LLC now owns 332,050 shares of the company’s stock worth $292,000 after buying an additional 240,134 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Veru during the second quarter worth $161,000. Institutional investors and hedge funds own 47.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of Veru in a research report on Thursday, January 2nd. Oppenheimer reissued an “outperform” rating and issued a $5.00 price objective on shares of Veru in a report on Tuesday, November 5th.

Veru Price Performance

NASDAQ:VERU opened at $0.74 on Wednesday. The company’s fifty day moving average price is $0.69 and its 200-day moving average price is $0.80. Veru Inc. has a 1-year low of $0.36 and a 1-year high of $1.92. The firm has a market capitalization of $108.95 million, a P/E ratio of -1.55 and a beta of -0.53.

Veru (NASDAQ:VERU) last announced its quarterly earnings results on Monday, December 16th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%. Equities analysts anticipate that Veru Inc. will post -0.3 EPS for the current fiscal year.

Veru Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.